← Back to Search

Radiation Therapy

60 Gy radiotherapy for Brain Tumor

Phase 2
Waitlist Available
Led By C. Leland Rogers, MD
Research Sponsored by Radiation Therapy Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from registration to 3 years
Awards & highlights

Study Summary

This trial is comparing observation with radiation therapy to see which is more effective in treating patients with meningioma.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from registration to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from registration to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free Survival Rate at 3 Years
Secondary outcome measures
Adherence to Protocol-specific Target and Normal Tissue Radiotherapy Parameters
Concordance Between Central and Parent Institution Histopathologic Grading/Subtyping
Greatest Single Dimension From MRI as Assessed by Central Neuroradiology Review at Diagnosis, at Progression, and at 3 Years
+7 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Intermediate RiskExperimental Treatment1 Intervention
54 Gy radiotherapy
Group II: High RiskExperimental Treatment1 Intervention
60 Gy radiotherapy
Group III: Low RiskActive Control1 Intervention
No treatment given.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
60 Gy radiotherapy
2009
Completed Phase 2
~250
54 Gy radiotherapy
2009
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Radiation Therapy Oncology GroupLead Sponsor
190 Previous Clinical Trials
64,683 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,932,909 Total Patients Enrolled
NRG OncologyOTHER
231 Previous Clinical Trials
100,608 Total Patients Enrolled

Media Library

3-dimensional conformal radiation therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00895622 — Phase 2
Brain Tumor Research Study Groups: Low Risk, Intermediate Risk, High Risk
Brain Tumor Clinical Trial 2023: 3-dimensional conformal radiation therapy Highlights & Side Effects. Trial Name: NCT00895622 — Phase 2
3-dimensional conformal radiation therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00895622 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many venues are currently hosting this research study?

"This medical trial is taking place at Kimmel Cancer Center at Thomas Jefferson University - Philadelphia in Philadelphia, Cross Cancer Institute at University of Alberta in Edmonton, and Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center in Savannah. In addition to these three sites, there are 75 other locations hosting this research."

Answered by AI

Is there any availability for prospective participants in this research?

"Information hosted on clinicaltrials.gov reveals that this medical study, first posted in June 2009 and last updated on May 14th 2021, is not recruiting patients at present but there are 156 other trials actively enrolling participants."

Answered by AI

Has the Federal Drug Administration given permission for 54 Gy radiotherapy?

"The safety of 54 Gy radiotherapy was scored as a 2 due to there being limited evidence supporting its efficacy and some data pointing towards its general safety."

Answered by AI
Recent research and studies
~15 spots leftby Apr 2025